Rituxan rundede lige 6 mia Schweizerfranc i Salg, stadig primært drevet i first line.
Roche in 2011: Strong results and positive outlook
Group sales rise 2% 1 (-10% in Swiss francs; +6% in US dollars), excluding Tamiflu.
Significant Foreign Exchange impact of -12 percentage points due to appreciation of the Swiss franc; overall Group sales at 42.5 billion Swiss francs.
Pharmaceuticals sales, excluding Tamiflu, up 1%, in line with the market; Diagnostics sales increase 6%, significantly ahead of the market.
Core earnings per share rise 11% due to solid operating performance, lower financing costs and a lower tax rate.
Core operating profit increases by 6%, significantly faster than sales, driven primarily by savings from the Operational
Excellence programme and continued productivity improvements.
Strong operating free cash flow of 13.7 billion Swiss francs, up 14%.
Net income increases by 26% to 9.5 billion Swiss Francs (+7% in Swiss Francs)
Excellent progress in late-stage pipeline: 17 out of 20 trials deliver positive results in 2011; targeted melanoma medicine Zelboraf and companion diagnostic test successfully launched in the US; marketing applications filed in US and EU for targeted cancer medicines Erivedge (vismodegib - US approval received January 2012) and pertuzumab.
Planned acquisition of Illumina to strengthen Roche Diagnostics' offering in DNA sequencing.
Board proposes a dividend increase of 3% to 6.80 Swiss francs, the 25th consecutive year of dividend growth.
Outlook for 2012: Low to mid-single-digit sales growth for Group and Pharma; Diagnostics to grow above the market; high single-digit Core EPS growth target; Roche will continue its attractive dividend policy.
Her deres outlook 2012:
Roche expects low to mid-single-digit sales growth at constant exchange rates for the Group and the Pharmaceuticals Division in 2012. Pharma sales growth is expected to accelerate, driven by the strength of its established product portfolio as well as planned new product launches. Sales by the Diagnostics Division are expected to again outpace the market.
Despite a challenging market environment, based on the expected sales growth and continued efficiency improvements, Roche is aiming for a high single-digit increase in Core Earnings per Share at constant exchange rates.
roche.pdf
Roche in 2011: Strong results and positive outlook
Group sales rise 2% 1 (-10% in Swiss francs; +6% in US dollars), excluding Tamiflu.
Significant Foreign Exchange impact of -12 percentage points due to appreciation of the Swiss franc; overall Group sales at 42.5 billion Swiss francs.
Pharmaceuticals sales, excluding Tamiflu, up 1%, in line with the market; Diagnostics sales increase 6%, significantly ahead of the market.
Core earnings per share rise 11% due to solid operating performance, lower financing costs and a lower tax rate.
Core operating profit increases by 6%, significantly faster than sales, driven primarily by savings from the Operational
Excellence programme and continued productivity improvements.
Strong operating free cash flow of 13.7 billion Swiss francs, up 14%.
Net income increases by 26% to 9.5 billion Swiss Francs (+7% in Swiss Francs)
Excellent progress in late-stage pipeline: 17 out of 20 trials deliver positive results in 2011; targeted melanoma medicine Zelboraf and companion diagnostic test successfully launched in the US; marketing applications filed in US and EU for targeted cancer medicines Erivedge (vismodegib - US approval received January 2012) and pertuzumab.
Planned acquisition of Illumina to strengthen Roche Diagnostics' offering in DNA sequencing.
Board proposes a dividend increase of 3% to 6.80 Swiss francs, the 25th consecutive year of dividend growth.
Outlook for 2012: Low to mid-single-digit sales growth for Group and Pharma; Diagnostics to grow above the market; high single-digit Core EPS growth target; Roche will continue its attractive dividend policy.
Her deres outlook 2012:
Roche expects low to mid-single-digit sales growth at constant exchange rates for the Group and the Pharmaceuticals Division in 2012. Pharma sales growth is expected to accelerate, driven by the strength of its established product portfolio as well as planned new product launches. Sales by the Diagnostics Division are expected to again outpace the market.
Despite a challenging market environment, based on the expected sales growth and continued efficiency improvements, Roche is aiming for a high single-digit increase in Core Earnings per Share at constant exchange rates.
roche.pdf
